Which stocks are experiencing notable movement on Wednesday? Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys.
Traders are paying attention to the gapping stocks in Wednesday's session. There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.
FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy Rocket Pharmaceuticals shares rise after FDA clears its pivotal RP-A501 trial for Danon disease with adjusted dosing and updated treatment protocol.
Wednesday's pre-market session: top gainers and losers As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Why Is Rocket Pharma Stock Up 15% Pre-Market Today? The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease.
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours Rocket Pharmaceuticals downgraded by BofA after FDA halts Danon disease trial; company pivots toward earlier-stage gene therapy programs.
What's going on in today's pre-market session Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety concerns.
Here are the top movers in Tuesday's session. Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
